Efficacy of COVID-19 control measures on post-vaccination outbreak in Italian Long Term Care Facilities: implications for policies.
COVID-19 vaccination
Long Term Care Facilities (LTCFS)
SARS CoV-2 infection
outbreak control measures
pandemic fatigue
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
11
2022
accepted:
16
05
2023
medline:
26
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Numerous individual and organizational factors can influence the spread of SARS-CoV-2 infection in Long Term Care Facilities (LTCFs). A range of outbreak control measures are still implemented in most facilities involving administrations, staff, residents and their families. This study aims to evaluate which measure could influence the transmission of SARS-CoV-2 infection among residents during the period March 2021-June 2022. We enrolled 3,272 residents aged ≥60 years. The outbreak control measures adopted to prevent or manage the infection included entry regulations, contact-regulating procedures, and virological surveillance of residents and staff. The association between LTCFs' and participants' characteristics with new cases of COVID-19 infections was analyzed using multilevel logistic regression models. In 33.8% of the facilities 261 cases of SARS-CoV-2 infection were reported. Among participant characteristics, gender and age were not associated with SARS-CoV-2 infection, while having received the vaccine booster dose was protective against infection [Odds Ratio (OR) = 0.34, 95% Confidence Interval (CI) 0.12-0.99, These data showed that vaccination booster doses and family visit restriction-control are still needed to make the LTCFs safer against SARS-CoV-2 infection.
Sections du résumé
Background
Numerous individual and organizational factors can influence the spread of SARS-CoV-2 infection in Long Term Care Facilities (LTCFs). A range of outbreak control measures are still implemented in most facilities involving administrations, staff, residents and their families. This study aims to evaluate which measure could influence the transmission of SARS-CoV-2 infection among residents during the period March 2021-June 2022.
Methods
We enrolled 3,272 residents aged ≥60 years. The outbreak control measures adopted to prevent or manage the infection included entry regulations, contact-regulating procedures, and virological surveillance of residents and staff. The association between LTCFs' and participants' characteristics with new cases of COVID-19 infections was analyzed using multilevel logistic regression models.
Results
In 33.8% of the facilities 261 cases of SARS-CoV-2 infection were reported. Among participant characteristics, gender and age were not associated with SARS-CoV-2 infection, while having received the vaccine booster dose was protective against infection [Odds Ratio (OR) = 0.34, 95% Confidence Interval (CI) 0.12-0.99,
Conclusions
These data showed that vaccination booster doses and family visit restriction-control are still needed to make the LTCFs safer against SARS-CoV-2 infection.
Identifiants
pubmed: 37346108
doi: 10.3389/fpubh.2023.1091974
pmc: PMC10280634
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1091974Informations de copyright
Copyright © 2023 Malara, Noale, Trevisan, Abbatecola, Borselli, Cafariello, Gareri, Fumagalli, Mossello, Volpato, Monzani, Coin, Okoye, Bellelli, Del Signore, Zia, Antonelli Incalzi, Palmieri, Fedele, Onder and The GeroCovid Vax Working Group.
Déclaration de conflit d'intérêts
SD was employed by Bluecompanion Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cochrane Database Syst Rev. 2021 Sep 15;9:CD015085
pubmed: 34523727
JAMA Netw Open. 2021 Mar 1;4(3):e211555
pubmed: 33724388
JAMA. 2020 Aug 18;324(7):619-620
pubmed: 32692848
Sci Rep. 2021 Sep 10;11(1):18093
pubmed: 34508133
Eur J Intern Med. 2021 May;87:29-35
pubmed: 33573885
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Front Med (Lausanne). 2021 Sep 22;8:715294
pubmed: 34631737
JAMA Netw Open. 2021 Mar 1;4(3):e216315
pubmed: 33787905
J Infect Dis. 2022 Feb 15;225(4):567-577
pubmed: 34618896
J Am Med Dir Assoc. 2022 Jan;23(1):15-18
pubmed: 34774494
J Am Med Dir Assoc. 2021 Feb;22(2):228-237.e25
pubmed: 33347846
J Am Med Dir Assoc. 2021 Oct;22(10):1969-1988
pubmed: 34428466
Vaccine. 2022 Apr 1;40(15):2324-2330
pubmed: 35248424